Explanation of how the number of participants for analysis was determined.
Includes whether analysis was per protocol, intention to treat, or another method.
Also provides relevant details such as imputation technique, as appropriate.

number of particpiants with stable, unstable, or no angina at baseline

[2]

Number of participants with at least one bifurcation lesion as determined by the angiographic core laboratory on the baseline angiogram

[3]

number of participants with blood pressure equal or higher than 130/85mmHg

[4]

number of particpants with diagnosed carotid artery disease at baseline

[5]

number of particpants with congestive heart failure at baseline

[6]

Number of participants that were smoking at baseline

[7]

All participants with diagnosed diabetes at baseline

[8]

number of male participants with a high-density lipoprotein (HDL)<40 and female particpants with a HDL<50 determined by the central chemistry laboratory

[9]

participants with hyperlipidemia at baseline

[10]

Number of participants with diabetes treated with insulin

[11]

Number of participants with medically treated diabetes.Excludes participants with diabetes treated with diet only.

[12]

number of participants that met the criteria of metabolic syndrome defined by the American Heart Association

[13]

number of participants with left ventricular ejection fraction <30% at baseline

[14]

Number of participants who had a myocardial infarction before baseline

[15]

number of participants who had a stroke before baseline

[16]

number of partipants who had a Transient Ischemic Attack before baseline

[17]

Number of participants with at least one total occlusion as determined by the angiografic core laboratory on the baseline angiogram

[18]

participants with Triglyceride levels ≥150 mg/dL as determined by a central chemistry laboratorium at baseline

[19]

Additive EuroSCORE is a prognostic scoring system calculating predicted operative mortality for patients undergoing cardiac surgery; it has been the most rigorously evaluated scoring system in cardiac surgery. A predetermined weighted score is assigned for specified patient-, cardiac-, and operation-related factors; for example, pulmonary hypertension is assigned a score of 2. The sum of scores is the additive EuroSCORE. EuroSCORE is calculated from site reported baseline data. A score of greater than 6 is considered as being predictive of an increased mortality risk. (www.euroscore.org)

[20]

Body Mass Index calculated from participants heigth and weight.

[21]

Average number of lesions per participant as determined by the investigator

[22]

The first scoring system in cardiac surgery to calculate mortality risk and to become popular was the Parsonnet risk stratification system, which was developed in the United States in the 1980s. A predetermined weighted score is assigned for several specified patient-, cardiac-, and operation-related factors; for example, dialysis is assigned a score of 10. A score of greater than 15 is considered as being predictive of an increased mortality risk. Parsonette score is calculated from baseline information.

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts
the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release
and can embargo communications regarding trial results for a period that is less than or equal to 60 days.
The sponsor cannot require changes to the communication and cannot extend the embargo.

The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release
and can embargo communications regarding trial results for a period that is more than 60 days but less than
or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.

Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.